首页> 外国专利> METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)

METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)

机译:使用iRNA组合物靶向因子XII(Hageman因子)治疗或预防与接触途径相关的疾病的方法(F12)

摘要

The present invention relates to methods of use of RNAi agents, e.g., double stranded RNAi agents, targeting a Factor XII (Hageman Factor (F12) gene, for treating subjects having a contact activation pathway-associated disease, such as a thrombophilia or hereditary angioedema (HAE), methods for preventing at least one symptom in a subject having a contact activation pathway-associated disease, such as a thrombus formation or an angioedema attack, and RNAi agents targeting an F12 gene, for use in the methods of the invention.
机译:本发明涉及靶向因子XII(Hageman因子(F12)基因)的RNAi剂,例如双链RNAi剂,用于治疗患有接触激活途径相关疾病例如血栓形成或遗传性血管性水肿的受试者的方法。 (HAE),用于预防患有与接触激活途径相关的疾病(例如血栓形成或血管性水肿发作)的受试者的至少一种症状的方法,以及靶向F12基因的RNAi剂,用于本发明的方法。

著录项

  • 公开/公告号US2020208150A1

    专利类型

  • 公开/公告日2020-07-02

    原文格式PDF

  • 申请/专利权人 ALNYLAM PHARMACEUTICALS INC.;

    申请/专利号US201816621754

  • 发明设计人 JAMES BUTLER;JINGXUAN LIU;

    申请日2018-07-06

  • 分类号C12N15/113;A61P9;

  • 国家 US

  • 入库时间 2022-08-21 11:22:26

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号